PUBLISHER: The Business Research Company | PRODUCT CODE: 1769712

PUBLISHER: The Business Research Company | PRODUCT CODE: 1769712

Plasma Protease C1-Inhibitor Global Market Report 2025

PUBLISHED: July 7, 2025

PAGES: 175 Pages

DELIVERY TIME: 2-10 business days

ADD TO COMPARE

SELECT AN OPTION

Description

Plasma protease C1-inhibitors are medications that suppress the activity of plasma protease C1 within the complement system. Their main function is to regulate immune system activity by preventing overactivation of the complement cascade and managing inflammation. These inhibitors help sustain equilibrium within immune and coagulation pathways, thereby protecting tissues from inflammatory damage.

The primary categories of medications that act on plasma protease C1-inhibitor include C1-inhibitors, C1-esterase inhibitors, recombinant inhibitors, kallikrein inhibitors, and selective bradykinin B2 receptor antagonists. C1-inhibitors are naturally occurring blood proteins that modulate the complement system, an essential part of the immune defense against infection and inflammation. These treatments are commonly available in injectable and lyophilized formulations and are distributed through hospital pharmacies, retail drugstores, and online pharmacy platforms.

The plasma protease C1-inhibitor market research report is one of a series of new publications from The Business Research Company that offers insights into plasma protease C1-inhibitor market statistics, including the global market size, regional distribution, leading competitors by market share, detailed market segmentation, industry trends, and emerging opportunities. This comprehensive research report provides an all-encompassing view of the industry, with detailed analysis of both the current landscape and future projections.

The plasma protease C1-inhibitor market size has grown rapidly in recent years. It will grow from $3.37 billion in 2024 to $3.85 billion in 2025 at a compound annual growth rate (CAGR) of 14.4%. Factors contributing to this historical growth include the rising prevalence of hereditary angioedema, increased awareness of rare genetic diseases, higher demand for biologics derived from plasma, improved diagnostics for C1-inhibitor deficiency, and expanded use of replacement therapy during emergency interventions.

The plasma protease C1-inhibitor market size is expected to see rapid growth in the next few years. It will grow to $6.53 billion in 2029 at a compound annual growth rate (CAGR) of 14.1%. Key drivers in the forecast period include a heightened emphasis on personalized treatment approaches, ongoing development of C1-inhibitor therapies in clinical pipelines, increasing preference for preventative treatment methods, broader access to at-home infusion solutions for C1-inhibitors, and greater recognition of C1-inhibitor deficiencies in preoperative and surgical contexts. Notable trends anticipated include a rise in orphan drug designations, advancements in low-immunogenicity drug formulations, incorporation of genomic technologies, expansion into telehealth platforms, and innovation in long-duration C1-inhibitor therapies.

The increasing investment in rare diseases is expected to drive the growth of the plasma protease C1-inhibitor market. Rare diseases are health conditions that impact a small percentage of the population, typically fewer than 1 in 2,000 individuals. These conditions are often chronic, progressive, and can be life-threatening or disabling. The rise in investment stems from the growing awareness of unmet medical needs and the potential for substantial returns through regulatory incentives such as orphan drug designation, market exclusivity, and lower development costs. This investment supports the development of plasma protease C1-inhibitors by funding research and innovation aimed at treating hereditary angioedema and other rare conditions linked to C1-inhibitor deficiencies, which can cause severe symptoms. For example, in April 2024, Global Genes, a US-based nonprofit organization, reported that companies developing drugs for rare diseases raised $7.1 billion in the first quarter of 2024, a 307% increase from the $1.8 billion raised in the same period in 2023. As a result, the increasing investment in rare diseases is propelling the plasma protease C1-inhibitor market forward.

Leading companies in the plasma protease C1-inhibitor market are concentrating on the development of advanced products, such as injectable prescription medicines, to provide rapid and effective relief for hereditary angioedema and enhance treatment results. Injectable prescription medicines are administered through injection and work by restoring or replacing plasma protease C1-inhibitor levels to control inflammation and prevent swelling episodes. For instance, in December 2022, Takeda Pharmaceutical Company Limited, a Japan-based pharmaceutical firm, introduced CINRYZE in India. CINRYZE is the first injectable C1 esterase inhibitor approved by the FDA for prophylactic treatment in patients aged six years and older. It helps reduce the frequency, severity, and duration of hereditary angioedema (HAE) attacks by increasing plasma levels of C1-INH, thereby preventing excessive bradykinin production and controlling the associated swelling.

In December 2023, Danaher Corporation, a US-based conglomerate, acquired Abcam plc for $5.7 billion. This acquisition was intended to strengthen Danaher's life sciences portfolio by improving its protein research tools and accelerating progress in disease mapping and drug discovery. Abcam plc is a UK-based biotechnology firm that offers various products related to plasma protease C1-inhibitor.

Major players in the plasma protease c1-inhibitor market are Takeda Pharmaceutical Company Limited, CSL Behring LLC, Sigma-Aldrich Co. LLC, Octapharma AG, Bio-Techne Corp, Ionis Pharmaceuticals Inc., Sanquin, Biotest AG, BioCryst Pharmaceuticals Inc., Pharming Group N.V., Sino Biological Inc, Cayman Chemical, Enzo Life Sciences Inc, KalVista Pharmaceuticals Inc., Santa Cruz Biotechnology Inc, Pharvaris N.V, Attune Pharmaceuticals Inc., Biorbyt Ltd, Adverum Biotechnologies Inc, and Lev Pharmaceuticals.

North America was the largest region in the plasma protease C1-inhibitor market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in plasma protease C1-inhibitor report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the plasma protease C1-inhibitor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The plasma protease C1-inhibitor market consists of sales of berinert, cinryze, haegarda, firazyr, and lcatibant. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Plasma Protease C1-Inhibitor Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on plasma protease c1-inhibitor market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for plasma protease c1-inhibitor ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The plasma protease c1-inhibitor market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Drug Class: C1-Inhibitors; C1-Esterase Inhibitor; Recombinant Inhibitor; Kallikrein Inhibitor; Selective Bradykinin B2 Receptor Antagonist
2) By Dosage Form: Lyphophlised; Injectables
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Subsegments:
1) By C1-Inhibitors: Plasma-Derived C1-Inhibitor; Recombinant C1-Inhibitor
2) By C1-Esterase Inhibitor: Intravenous (IV) C1-Esterase Inhibitor; Subcutaneous (SC) C1-Esterase Inhibitor
3) By Recombinant Inhibitor: Recombinant Human C1-Inhibitor; Recombinant Analog Inhibitor
4) By Kallikrein Inhibitor: Plasma Kallikrein Inhibitor; Oral Kallikrein Inhibitor
5) By Selective Bradykinin B2 Receptor Antagonist: Injectable B2 Receptor Antagonist; Oral B2 Receptor Antagonist
Companies Mentioned: Takeda Pharmaceutical Company Limited; CSL Behring LLC; Sigma-Aldrich Co. LLC; Octapharma AG; Bio-Techne Corp
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r36027

1. Executive Summary

2. Plasma Protease C1-Inhibitor Market Characteristics

3. Plasma Protease C1-Inhibitor Market Trends And Strategies

4. Plasma Protease C1-Inhibitor Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Plasma Protease C1-Inhibitor Growth Analysis And Strategic Analysis Framework

5.1. Global Plasma Protease C1-Inhibitor PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Plasma Protease C1-Inhibitor Market Growth Rate Analysis
5.4. Global Plasma Protease C1-Inhibitor Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Plasma Protease C1-Inhibitor Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Plasma Protease C1-Inhibitor Total Addressable Market (TAM)

6. Plasma Protease C1-Inhibitor Market Segmentation

6.1. Global Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
C1-Inhibitors
C1-Esterase Inhibitor
Recombinant Inhibitor
Kallikrein Inhibitor
Selective Bradykinin B2 Receptor Antagonist
6.2. Global Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Lyphophlised
Injectables
6.3. Global Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
6.4. Global Plasma Protease C1-Inhibitor Market, Sub-Segmentation Of C1-Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Plasma-Derived C1-Inhibitor
Recombinant C1-Inhibitor
6.5. Global Plasma Protease C1-Inhibitor Market, Sub-Segmentation Of C1-Esterase Inhibitor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Intravenous (IV) C1-Esterase Inhibitor
Subcutaneous (SC) C1-Esterase Inhibitor
6.6. Global Plasma Protease C1-Inhibitor Market, Sub-Segmentation Of Recombinant Inhibitor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Recombinant Human C1-Inhibitor
Recombinant Analog Inhibitor
6.7. Global Plasma Protease C1-Inhibitor Market, Sub-Segmentation Of Kallikrein Inhibitor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Plasma Kallikrein Inhibitor
Oral Kallikrein Inhibitor
6.8. Global Plasma Protease C1-Inhibitor Market, Sub-Segmentation Of Selective Bradykinin B2 Receptor Antagonist, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Injectable B2 Receptor Antagonist
Oral B2 Receptor Antagonist

7. Plasma Protease C1-Inhibitor Market Regional And Country Analysis

7.1. Global Plasma Protease C1-Inhibitor Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Plasma Protease C1-Inhibitor Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Plasma Protease C1-Inhibitor Market

8.1. Asia-Pacific Plasma Protease C1-Inhibitor Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Plasma Protease C1-Inhibitor Market

9.1. China Plasma Protease C1-Inhibitor Market Overview
9.2. China Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Plasma Protease C1-Inhibitor Market

10.1. India Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Plasma Protease C1-Inhibitor Market

11.1. Japan Plasma Protease C1-Inhibitor Market Overview
11.2. Japan Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Plasma Protease C1-Inhibitor Market

12.1. Australia Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Plasma Protease C1-Inhibitor Market

13.1. Indonesia Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Plasma Protease C1-Inhibitor Market

14.1. South Korea Plasma Protease C1-Inhibitor Market Overview
14.2. South Korea Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Plasma Protease C1-Inhibitor Market

15.1. Western Europe Plasma Protease C1-Inhibitor Market Overview
15.2. Western Europe Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Plasma Protease C1-Inhibitor Market

16.1. UK Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Plasma Protease C1-Inhibitor Market

17.1. Germany Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Plasma Protease C1-Inhibitor Market

18.1. France Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Plasma Protease C1-Inhibitor Market

19.1. Italy Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Plasma Protease C1-Inhibitor Market

20.1. Spain Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Plasma Protease C1-Inhibitor Market

21.1. Eastern Europe Plasma Protease C1-Inhibitor Market Overview
21.2. Eastern Europe Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Plasma Protease C1-Inhibitor Market

22.1. Russia Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Plasma Protease C1-Inhibitor Market

23.1. North America Plasma Protease C1-Inhibitor Market Overview
23.2. North America Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Plasma Protease C1-Inhibitor Market

24.1. USA Plasma Protease C1-Inhibitor Market Overview
24.2. USA Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Plasma Protease C1-Inhibitor Market

25.1. Canada Plasma Protease C1-Inhibitor Market Overview
25.2. Canada Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Plasma Protease C1-Inhibitor Market

26.1. South America Plasma Protease C1-Inhibitor Market Overview
26.2. South America Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Plasma Protease C1-Inhibitor Market

27.1. Brazil Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Plasma Protease C1-Inhibitor Market

28.1. Middle East Plasma Protease C1-Inhibitor Market Overview
28.2. Middle East Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Plasma Protease C1-Inhibitor Market

29.1. Africa Plasma Protease C1-Inhibitor Market Overview
29.2. Africa Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Plasma Protease C1-Inhibitor Market Competitive Landscape And Company Profiles

30.1. Plasma Protease C1-Inhibitor Market Competitive Landscape
30.2. Plasma Protease C1-Inhibitor Market Company Profiles
- 30.2.1. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. CSL Behring LLC Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Sigma-Aldrich Co. LLC Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Octapharma AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Bio-Techne Corp Overview, Products and Services, Strategy and Financial Analysis

31. Plasma Protease C1-Inhibitor Market Other Major And Innovative Companies

31.1. Ionis Pharmaceuticals Inc.
31.2. Sanquin
31.3. Biotest AG
31.4. BioCryst Pharmaceuticals Inc.
31.5. Pharming Group N.V.
31.6. Sino Biological Inc
31.7. Cayman Chemical
31.8. Enzo Life Sciences Inc
31.9. KalVista Pharmaceuticals Inc.
31.10. Santa Cruz Biotechnology Inc
31.11. Pharvaris N.V
31.12. Attune Pharmaceuticals Inc.
31.13. Biorbyt Ltd
31.14. Adverum Biotechnologies Inc
31.15. Lev Pharmaceuticals

32. Global Plasma Protease C1-Inhibitor Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Plasma Protease C1-Inhibitor Market

34. Recent Developments In The Plasma Protease C1-Inhibitor Market

35. Plasma Protease C1-Inhibitor Market High Potential Countries, Segments and Strategies

35.1 Plasma Protease C1-Inhibitor Market In 2029 - Countries Offering Most New Opportunities
35.2 Plasma Protease C1-Inhibitor Market In 2029 - Segments Offering Most New Opportunities
35.3 Plasma Protease C1-Inhibitor Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer

Have a question?

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Christine Sirois

Manager - Americas

+1-860-674-8796

SEE OUR FAQ